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Objective: To assess the efficacy and safety
of an association of diallyl thiosulfinate with
nuciferine and diosgenin in the treatment of a group of patients
suffering from premature ejaculation (PE), primary or second-
ary to erectile dysfunction (ED).
Materials and methods: From July 2015 to October 2016, 143
patients (mean age 25.3; range 18-39) affected by PE complet-
ed the study and were finally analyzed in this phase I study. 
All patients, after clinical assessment and laboratory evaluation
were asked to take an association of diallyl thiosulfinate with
nuciferine and diosgenin as oral tablet, once a day, on alternate
days, for three months. At the baseline and after three months
of treatment, each patient was asked to complete the following
questionnaires: International Index of Erectile Function 
(IIEF-5), Premature Ejaculation Diagnostic Tool (PEDT), 
Male Sexual Health Questionnaire (MSHQ).
Results: A statistical significant improvement in terms of erec-
tile function, comparing the IIEF-5 value at baseline and fol-
low-up visit was found (respectively IIEF-5: 8.7 vs 14.01;
p < 0.001). Moreover, at follow-up visit, 97/143 men (67.8%)
referred a subjective improvement of the erection quality and a
better control of the ejaculation (PROs). The IELT improved
too between the baseline evaluation and the follow-up visit 
(p < 0.001).
Conclusion: In conclusion, our study, even if supported by pre-
liminary results, showed how Diallyl Thiosulfinate, Nuciferine
and Diosgenin is able to improve the control of ejaculation in
patients suffering from PE, primary or secondary to ED without
any significant adverse effects.
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with prevalence rates of 20-30%, probably affecting
every man at some point in his life (2, 3). It may result
in unsatisfactory sexual intercourse for both partners,
decreasing sexual self-confidence and self-esteem and
resulting in an overall reduction of quality of life (QoL)
(4). Lifelong PE occurs within 30-60 seconds after vagi-
nal penetration with nearly every coitus, interesting
about > 85% of men affected by this dysfunction, where-
as about 10-20% of men ejaculate within 1-2 minutes
(5). Acquired PE is commonly due to sexual perform-
ance anxiety (6), psychological or relationship problems
(6), erectile dysfunction (ED) (7), occasionally prostatitis
(8), hyperthyroidism (9), or during withdrawal/detoxifi-
cation from prescribed (10) or recreational drugs (11).
In addition, men with this dysfunction are usually older,
have a higher mean body max index and a greater inci-
dence of comorbid disease and ED associated to lifelong,
variable and subjective PE (12, 13). Although the patho-
physiologic mechanism of lifelong PE is not fully under-
stood, it is shown that psychosocial, as well as organic
factors play a key role in the aetiology (14-16). Several
studies demonstrated that patients with PE have more
dorsal penile nerves, increasing glands penile hypersen-
sivity and hyperexcitability (17). Moreover, they also
usually have other abnormal autonomic reflex pathways
for the ejaculatory process, including shorter bulbo-cav-
ernosal latency time and higher bulbo-cavernosal evoked
potentials (18, 19). For this reason, pharmacologic ther-
apy that reduce glands penile hypersensivity should be
effective for the treatment of PE. Medications, coun-
selling and sexual techniques, that may delay ejacula-
tion, can help the patients to improve sexual intercourse.
However, a combination of these factors could be the
best choice of treatment to improve efficacy and mini-
mize relapse (20). Behavioural therapy essentially
include the “stop-start program” developed by Semans
(21), and its modification, the “squeeze” technique, pro-
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INTRODUCTION
Premature ejaculation (PE) is defined as uncontrolled
ejaculation either before or shortly after sexual penetra-
tion (1). It is a very common male sexual dysfunction
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posed by Masters and Johnson (22). All these approaches
need the partner’s cooperation for a long time, resulting
often difficult in the long term (23). Pharmacological
therapy includes: selective serotonin reuptake inhibitors
(SSRIs) antidepressants (24); dapoxetine (25); anaesthet-
ic creams (26) and phosphodiesterase type 5 inhibitors
(PDE5i) (27). Also some natural compounds (i.e.
Satureja montana, Tribulus terrestris, Phyllantus emblica)
proved to be efficient in improving sexual quality of life
in patients with PE (28). The role of nutraceuticals
seems, then, interesting in the management of PE. 
The aim of this study was to assess the efficacy and safe-
ty of Diallyl Thiosulfinate, Nuciferine and Diosgenin
(CAMPEDEX-5®) in the treatment of patients affecting by
PE, primary or secondary to ED.
MATERIALS AND METHODS
Study design
From July 2015 to October 2016, we enrolled, in a pilot
study, a total of 154 patients, affecting by PE, primary or
secondary to ED. Each patient signed a written fully
informed consent statement before being enrolled in the
study and accepted the trial voluntarily. After enrolment,
all patients were asked to take CAMPEDEX-5® oral tablet,
once a day, on alternate days, for three months (Figure 1).
After 30 days all contacted by phone in order to be sure
about the adherence to study protocol. After 3 months, all
patients were evaluated with clinical evaluation and ques-
tionnaires in order to test the treatment efficacy and safety.
Inclusion and exclusion criteria
All men had been in stable, monogamous, heterosexual
relationship with at least one sexual intercourse a week
with a compliant female partner. Exclusion criteria were:
age < 18 years, history of a psychiatric or neurological
disorder, alcohol or drug abuse, previous genitourinary
system trauma or surgery, spinal cord injury, previous
radiotherapy, thyroid diseases, hypogonadism, currently
taking a drug known to affect sexual function, such as
hormonal therapy for prostate cancer.
Baseline evaluation
The aetiology of PE was determined, in all cases, by a
complete in-depth medical history, physical examina-
tion, hormonal evaluation and patient self-administered
questionnaires on sexual function, even submitted to the
partners. All the patients received a urological visit that
considered the development of external genitalia, the
presence of phimosis and/or prepuce anomalies. At the
baseline, we collected the following hormonal profile
from all patients: serum follicle-stimulating hormone (FSH)
concentrations, prolactin levels, thyroid stimulating hor-
mone (TSH), luteinizing hormone (LH) and blood total
testosterone (TT). Each patient was asked to complete the
following questionnaires: International Index of Erectile
Function (IIEF-5), Premature Ejaculation Diagnostic Tool
(PEDT) and Male Sexual Health Questionnaire (MSHQ). 
Questionnaires and PE status evaluation
The IIEF-5 scale was used in order to evaluate the erec-
tile function in the last six months considering the sever-
ity of ED, classified as follow: severe (IIEF-5 ≤ 7), mod-
erate (IIEF-5 between 8 and 11), mild-moderate (IIEF-5
between 12 and 16), mild (IIEF-5 17-21), absent (IIEF-
5 between 22 and 25). PEDT help to identify men who
may have a problem with ejaculating too soon during
sexual activity, considering the ejaculation as the release
of semen after penetration. PEDT investigated the sever-
ity of PE, classified as follow: absence of PE (PEDT ≤ 8),
probably PE (PEDT 9-10), certainly present PE (PEDT
≥ 11) (29). MSHQ-EjD is an abridged version of the 25-
item MSHQ, seen as a validated, self-administered
instrument for assessing the primary domains of erec-
tion, ejaculation, and sexual satisfaction in aging men.
MSHQ-EjD described three ejaculatory function items,
investigating force (“in the past month, how would you rate
the strength or force of your ejaculation?”), volume item
(“in the past month, how would you rate the amount or vol-
ume of semen or fluid when you ejaculate?”), frequency item
(“in the past month, how often have you been able to ejacu-
late or “cum” when having sexual activity?), and one ejacu-
lation bother item (“if you had any ejaculation difficulties or
have been unable to ejaculate, have you been bothered by
this?”) (30). Ejaculatory function score, which is the sum
of the ordinal responses to the three items, ranges from
1 to 15, while bother scores ranges from 0 to 5. 
Furthermore, we collected the Intravaginal Ejaculation
Latency Time (IELT), as the time from vaginal penetration
until ejaculation (31). It was timed on a stopwatch by
‘start’ (penetration) to ‘stop’ (ejaculation). IELT was asked
Figure 1. 
The figure shows the study schedule. 
IIEF-5: International Index of Erectile Function; PEDT: Premature Ejaculation Diagnostic Tool; MSHQ-EjD: Male Sexual Health
Questionnaire; IELT: Intravaginal ejaculation latency time; PROs: Patients-Reported Outcomes.
both to men and their partners, trying to be honest in
recording the time and it was calculated as mean from that
perceived by the men and that perceived by partners.
They were instructed to calculate and record the exact
time after ejaculation.
Follow-up evaluation
At 3 months follow-up evaluation, all patients under-
went urological examination and the same laboratory
and questionnaires evaluation as at the baseline time. 
In addition, we evaluated the Patients-Reported Outcomes
(PROs). PROs are defined as a report that comes direct-
ly from the patient about the status of his health condi-
tion without amendment or interpretation of the
patient’s response by a clinician or anyone else (32). 
The “outcomes” in PRO were interpreted broadly to
reflect a variety of information reported directly by the
patient, investigating the presence of a subjective
improvement of erection quality and a positive change of
the control of PE. Also health-related QoL, functional
status and treatment adherence were collected.
Outcome measures and statistical analysis
All clinical, laboratory and parameters and question-
naires were compared at the baseline (before to begin
treatment) and at follow-up visit (after three months of
treatment). All statistical analysis was performed using
the IBM SPSS version 20.0 (SPSS Inc, Chicago, IL, USA).
P < 0.05 was considered statistically significant.
RESULTS
Of all 154 men enrolled, 143 patients completed the study
voluntarily, 11 patients withdrew the study for personal
reasons. 81/143 men (56.6%) had a clinical presentation
of lifelong PE, while 62/143 men (43.3%) presented a sec-
ondary PE, caused by sexual performance anxiety, psy-
chological or relationship problems and occasionally pro-
statitis. 44/143 patients (30.7%) had ED associated. The
mean age was 25.3 years old (range 18-39). At baseline
and follow-up visit, all hormonal parameters collected
were in the normal range (Table 1). How shown in Table
2, at the follow-up visit, the patients shown a statistical
significant improvement in terms of erectile function,
comparing the IIEF-5 value at baseline and follow-up visit
(respectively IIEF-5: 8.7 vs 14.0; p < 0.001). Median total
PEDT score changed from 15 (baseline) to 10 (follow-up).
Regarding MSHQ-EjD, the majority of patients reported,
at the end of treatment, a reduction of awkwardness dur-
ing sexual intercourses (bother score: 5 vs 3) and an
improvement of ejaculatory function disorders (ejaculato-
ry function score: 9 vs 12). IELT shown a clean improve-
ment, increasing significantly from 45.5 sec to 123.7 sec,
respectively at baseline and follow-up visit (p < 0.001)
(Figure 2). Moreover, at follow-up visit, of all 143
patients, 97/143 men (67.8%) referred a subjective
improvement of the erection quality and a better control
of the ejaculation (PROs). During the study, no treatment
emergent adverse events occurred, let alone some patients
interrupted the drug assumption for concomitant thera-
pies or co-morbidities.
DISCUSSION
Main finding
In this study, we demonstrated how the assumption of
organic compounds derived from natural substances is
able to improve the quality of erections and the control
of ejaculation, increasing the mean ejaculation latency
time. In particular, we tested the following combination
of Diallyl Thiosulfinate (20 mg), Nuciferine (137.5 mg)
and Diosgenin (45 mg).
Results in the context of previous studies
Thiosulfinates are allylsulfide compounds including
allicin, diallyldisulfide, diallyltrisulfide, S-allylmercapto-
cysteine and S-allylcysteine, a class of phytochemical
organosulfurs found essentially in garlic and other veg-
etables from Alliumspecies (33). Allicin, or Diallyl
Thiosulfinate, is the most important and representative
active ingredient of garlic (Allium sativus). This substance
is formed when the clumps that make up the bulbs are
cut, chewed or otherwise crushed. Following these
mechanical actions, an enzyme, called allinase, releases
from the vacuolary juices, acting on an aminoacid, the
allyl, transforming it into allicin. Diallyl Thiosulphinate
can increase the concentration of intracellular glu-
tathione, a substance consisting of three amino-acids
(cysteine, glutamic acid and glycine). Through a series of
reactions, cysteine is transformed in hydrogen sulphide
(H2S) produced at the arterial level with particular refer-
ence to peripheral circulation. H2S acts as a real pro-
erogenous gaseous mediator which, through the opening
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Table 1. 
Clinical and laboratory characteristics of all analyzed patients.
Demography, clinical and laboratory characteristics at baseline
Enrolled patients n° 143
Age (mean) (range) 25.3 (18-39)
Clinical presentation
Primary PE 81
Secondary PE 62
Associated ED 44
Total testosterone (ng/ml) 14.3
FSH (IU/L) 5.3
LH (IU/L) 6.8
TSH (mIU/L) 2.3
Prolactin (ng/ml) 7.8
Table 2. 
Outcome variables before and after treatment.
Outcomes variable Baseline Follow-up P
IIEF-5 (mean score) 8.7 14.01 < 0.001
PEDT (mean score) 15 10 < 0.1
MHSQ-EjD 
(ejaculatory function mean score) 9 12 < 0.1
MHSQ-EjD 
(bother mean score) 5 3 < 0.1
IELT (mean score) [min] 45.5 123.7 < 0.001
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of potassium channel ATP, resulting in increased CA+
ion transfer, produces through a precise hyperpolariza-
tion mechanism on smooth muscle cells, a relaxation
effect on them. The relaxation of the peripheral smooth
muscle also causes the recall of blood resulting in an
erection phenomenon (34). 
Diosgenine is the most important active principle of
Dioscorea (Dioscorea villosa), also known as wild yam, a
plant belonging to the Dioscoreacee family. It is therefore
an important precursor of steroids, present in nature in
the form of diocin glycoside or other heterosides that are
then hydrolysed in acidic environments and has there-
fore always been used by the pharmaceutical industry as
a raw material for the production of hormones, such as
DHEA. Small amounts of DHEA are also produced by
testicles, ovaries and glial cells. DHEA circulates blood-
stream especially as a sulfate (DHEA-S); in the plasma
about 80% of this sulphate is bound to albumin, while
the remaining 20% is linked to lipoproteins. The amount
of DHEA contained in the human body is related to the
age of the subject. After birth there is a significant
decrease in plasma levels of DHEA. Starting at five years,
levels are rising again to reach the peak of the age of
twenty-five; From the age of twenty-five, there is a pro-
gressive decrease in the concentration of DHEA in the
body; this decline begins to become rapid from forty
years. At eighth decade, the level does not exceed 10% of
the maximum reached twenty-five years. Because of this
decrease in plasma levels with age, many authors have
suspected that DHEA was heavily involved in aging-reg-
ulating processes, so DHEA administration was recom-
mended as an anti-aging method. DHEA appears to be
involved in many biological functions including sexual
activity regulation and stimulation, myelin production
and activation of the G6PD-H enzyme that helps to
reduce fat cells (35). Nuciferine is an alkaloid extracted
from the plants Nymphaea caerulea and Nelumbo
nucifera. It has a pharmacological profile of action asso-
ciated with dopamine receptor blockade. Specifically,
Nuciferine is a partial antagonist of D2-like receptor, a
subtype of Dopamine receptors which activation is asso-
ciated with ejaculation and micturition stimulus (36). 
It induces sedation, hypothermia, ptosis, and catalepsy, if
present in higher doses; it inhibits spontaneous motor
activity, conditioned avoidance response, amphetamine
toxicity and stereotypy. A clinical trial on rats showed that
Nuciferin, at doses ranging from 25 to 50 mg per kg
intraperitoneal, is able to produce sedation levels from
moderate to marked and ptosis. 
The authors have therefore concluded that probably
Nuciferin acts by blocking dopaminergic receptors: in a
further study it has been shown that this substance is able
to inhibit amphetamine-induced stereotype, which, as is
known, is mediated by the stimulation of dopaminergic
receptors (36). 
This present study showed that IELT significantly
increased after treatment with CAMPEDEX-5®. 
Moreover, Diallyl Thiosulfinate, Nuciferine and Diosgenin
Figure 2. 
The figure shows the results at the follow-up evaluation by using questionnaires before (pre) and after (post) treatment. 
IIEF-5: International Index of Erectile Function; PEDT: Premature Ejaculation Diagnostic Tool; MSHQ-EjD: Male Sexual Health
Questionnaire; IELT: Intravaginal ejaculation latency time; PROs: Patients-Reported Outcomes.
proved effective in improving the quality of erections,
increasing significantly IIEF-5. Topical agents, for the
treatment of PE, can reduce the hypersensivity of the
glands penis, but can induce localized irritation, including
pain, burning, delayed ejaculation and loss of penile sen-
sation (37). Furthermore, in our study, the treatment with
CAMPEDEX-5® was well tolerated by all patients, no
showing any side effect reported during the period study.
However, the limitation of the study is related to the
methodology used, as it was not a case-control study.
More studies should be carried out to clarify the precise
role of the active ingredients in CAMPEDEX-5® and their
interactions.
CONCLUSIONS
Our study, though based on results obtained from a pilot
study, shown how Diallyl Thiosulfinate, Nuciferine and
Diosgenin are able to improve the control of ejaculation in
patients suffering from PE, primary or secondary to ED,
significantly improving IIEF and IELT rates. The drug had
thus proven to be safe and effective in the treatment of PE,
without having clinically relevant side effects.
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